Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H1 2020’, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

– The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects

– The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Amgen Inc

Argenx SE

Biotest AG

Chengdu Rongsheng Pharmaceutical Co Ltd

Clover Biopharmaceuticals

CSL Ltd

Enzene Biosciences Ltd

Genosco Inc

Genzyme Corp

HanAll Biopharma Co Ltd

Hutchison MediPharma Ltd

Jiangsu Hengrui Medicine Co Ltd

Kezar Life Sciences Inc

KM Biologics Co Ltd

Momenta Pharmaceuticals Inc

Novartis AG

Pfizer Inc

Pharmagenesis Inc

Pharmapraxis

Principia Biopharma Inc

Protalex Inc

Qilu Pharmaceutical Co Ltd

Rigel Pharmaceuticals Inc

Shandong Quangang Pharmaceutical Co Ltd

Sichuan Kelun Pharmaceutical Co Ltd

Taiho Pharmaceutical Co Ltd

UCB SA

Table of Contents

Table of Contents

Introduction

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Overview

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics Development

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics Assessment

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Companies Involved in Therapeutics Development

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Drug Profiles

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Dormant Projects

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Discontinued Products

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by 3SBio Inc, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Amgen Inc, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Argenx SE, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Biotest AG, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Clover Biopharmaceuticals, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by CSL Ltd, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Enzene Biosciences Ltd, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Genosco Inc, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Genzyme Corp, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by HanAll Biopharma Co Ltd, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Hutchison MediPharma Ltd, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Kezar Life Sciences Inc, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by KM Biologics Co Ltd, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Momenta Pharmaceuticals Inc, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Novartis AG, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Pfizer Inc, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Pharmagenesis Inc, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Pharmapraxis, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Principia Biopharma Inc, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Protalex Inc, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Qilu Pharmaceutical Co Ltd, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Rigel Pharmaceuticals Inc, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Shandong Quangang Pharmaceutical Co Ltd, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Taiho Pharmaceutical Co Ltd, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by UCB SA, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Dormant Projects, H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Dormant Projects, H1 2020 (Contd..1), H1 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports